210 related articles for article (PubMed ID: 29535672)
21. Ocular manifestation and generalization after ocular onset in ocular myasthenia gravis: A 5-year analysis.
Kemchoknatee P; Arepagorn A; Srisombut T
Asian Pac J Allergy Immunol; 2021 Oct; ():. PubMed ID: 34717528
[TBL] [Abstract][Full Text] [Related]
22. [Prognosis of thymectomy in treatment of ocular myasthenia gravis and relevant influencing factors].
Deng Y; Zhang X
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(27):1922-5. PubMed ID: 19953918
[TBL] [Abstract][Full Text] [Related]
23. Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China.
Ding J; Zhao S; Ren K; Dang D; Li H; Wu F; Zhang M; Li Z; Guo J
BMC Neurol; 2020 Jun; 20(1):238. PubMed ID: 32527235
[TBL] [Abstract][Full Text] [Related]
24. Risk for generalization in ocular onset myasthenia gravis: experience from a neuro-ophthalmology clinic.
Kısabay A; Özdemir HN; Gökçay F; Çelebisoy N
Acta Neurol Belg; 2022 Apr; 122(2):337-344. PubMed ID: 33544334
[TBL] [Abstract][Full Text] [Related]
25. Outcome and clinical features in juvenile myasthenia gravis: A systematic review and meta-analysis.
Lin Y; Kuang Q; Li H; Liang B; Lu J; Jiang Q; Yang X
Front Neurol; 2023; 14():1119294. PubMed ID: 36970540
[TBL] [Abstract][Full Text] [Related]
26. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
[TBL] [Abstract][Full Text] [Related]
27. Risk Factors for Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study.
Guo RJ; Gao T; Ruan Z; Zhou HY; Gao F; Xu Q; Yu LP; Wu SD; Lei T; Li HH; Sun C; Zhang M; Gao YW; Lu XD; Tang YL; Tang BL; Huo FY; Zhu Y; Li ZY; Chang T
Neurol Ther; 2022 Mar; 11(1):73-86. PubMed ID: 34729706
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of 424 childhood-onset myasthenia gravis patients.
Gui M; Luo X; Lin J; Li Y; Zhang M; Zhang X; Yang M; Wang W; Bu B
J Neurol; 2015; 262(4):823-30. PubMed ID: 25588729
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcome of juvenile myasthenia gravis after extended transsternal thymectomy in a chinese cohort.
Cheng C; Liu Z; Xu F; Deng Z; Feng H; Lei Y; Zou J; Yeung SC
Ann Thorac Surg; 2013 Mar; 95(3):1035-41. PubMed ID: 23374447
[TBL] [Abstract][Full Text] [Related]
30. Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
Fisher KS; Gill J; Todd HF; Yang MB; Lopez MA; Abid F; Lotze T; Shah VS
Pediatr Neurol; 2021 May; 118():12-19. PubMed ID: 33684630
[TBL] [Abstract][Full Text] [Related]
31. Spontaneous remission in juvenile myasthenia gravis: A cohort of 13 cases and review of the literature.
Arroyo HA; Torres AR
Neuromuscul Disord; 2022 Mar; 32(3):213-219. PubMed ID: 35094888
[TBL] [Abstract][Full Text] [Related]
32. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.
Kupersmith MJ
J Neurol; 2009 Aug; 256(8):1314-20. PubMed ID: 19377863
[TBL] [Abstract][Full Text] [Related]
33. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
Allen JA; Scala S; Jones HR
Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
[TBL] [Abstract][Full Text] [Related]
34. Acetylcholine receptor antibodies in juvenile myasthenia gravis.
Andrews PI; Massey JM; Sanders DB
Neurology; 1993 May; 43(5):977-82. PubMed ID: 8492956
[TBL] [Abstract][Full Text] [Related]
35. Cell-Based Versus Enzyme-Linked Immunosorbent Assay for the Detection of Acetylcholine Receptor Antibodies in Chinese Juvenile Myasthenia Gravis.
Yan C; Li W; Song J; Feng X; Xi J; Lu J; Zhou S; Zhao C
Pediatr Neurol; 2019 Sep; 98():74-79. PubMed ID: 31307830
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for ocular myasthenia gravis: an observational study in Japan.
Narita T; Nakane S; Nagaishi A; Minami N; Niino M; Kawaguchi N; Murai H; Kira JI; Shimizu J; Iwasa K; Yoshikawa H; Hatanaka Y; Sonoo M; Shimizu Y; Matsuo H
Ther Adv Neurol Disord; 2023; 16():17562864231163819. PubMed ID: 37051222
[TBL] [Abstract][Full Text] [Related]
37. Antibody profile may predict outcome in ocular myasthenia gravis.
Galassi G; Mazzoli M; Ariatti A; Kaleci S; Valzania F; Nichelli PF
Acta Neurol Belg; 2018 Sep; 118(3):435-443. PubMed ID: 29858757
[TBL] [Abstract][Full Text] [Related]
38. Rituximab in juvenile myasthenia gravis-an international cohort study and literature review.
Ramdas S; Della Marina A; Ryan MM; McWilliam K; Klein A; Jacquier D; Alabaf S; Childs AM; Parasuraman D; Beeson D; Palace J; Jungbluth H
Eur J Paediatr Neurol; 2022 Sep; 40():5-10. PubMed ID: 35835035
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
40. Childhood myasthenia gravis: clinical features and outcomes.
Sri-udomkajorn S; Panichai P; Liumsuwan S
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
